Genetic risk factor associated with claw problems in dogs identified
Researchers at the Swedish University of Agricultural Sciences (SLU), Norwegian School of veterinary Science (NVH), and Uppsala University (UU) have identified one of the genetic risk factors responsible for development of an autoimmune disease affecting the claws. The study is an example of a well-established collaboration between geneticists and veterinarians at the three universities.
A disease called Symmetrical Lupoid Onychodystrophy (SLO), which is an immune-mediated disease with suspected autoimmune etiology, causes the claw problems that were analyzed. This means that the body’s own immune system reacts abnormally which leads to sloughing of claws from claw beds.
As the disease progresses all claws will become affected and this ultimately leads to destruction of the underlying claw tissue and deformation of the claws. The disease is painful and involves large degree of pain and suffering for affected dogs.
The identified genetic risk factors are genes in the major histocompatibility complex (MHC) class II region that encodes proteins that control the immune response. These genes have been shown to be important genetic risk factors for different autoimmune diseases in both dogs and humans.
When the immune system is activated, MHC proteins determine towards which molecules the attack should be directed. In autoimmunity, MHC proteins will erroneously recognize the body’s self-molecules and trigger destruction of the body’s own tissues and organs. Such disturbances can, in certain cases, result in development of autoimmune diseases like for example SLO.
A major increased risk for SLO development was found in Gordon Setter dogs that had inherited the MHC class II risk type from both parents. In dogs that had inherited the two variants from either parents it was found that the effect of the protective type dominated and such dogs were healthy.
Most read news
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.